The Efficacy and Safety of Venglustat Compared With Cerezyme in Pediatric Participants 2 to 11 Years of Age With Gaucher Disease Type 3 (GD3)

What this study involves

The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.

Study type

Interventional

Phase

Phase 3

Age range

2 years - 11 years

Sex eligible

All sexes

Healthy volunteers

Not accepted

Participants

18 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

This is a Phase 3, multi-center, multi-national, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat in pediatric (age ≥2 years to ≤11 years) participants with GD3 who have been treated with ERT for at least 2 years, and have met therapeutic goals. Study details include: Study duration: a 52-week primary analysis period and a 52-week extended treatment period.

Treatment frequency:

• Daily tablets for venglustat for participants randomized to venglustat arm during primary analysis period and for all patients during extended treatment period.
• Cerezyme infusion every 2 weeks for participants randomized to Cerezyme arm during primary analysis period and, if needed, as rescue medication for participants in venglustat treated arm during primary analysis period or for any participant during extended treatment period.

Visit frequency: every 12 to 14 weeks during primary treatment period and 12-26 weeks during extended treatment period.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

• Pediatric participants who are 2 to 11 years of age inclusive, at the time of signing the informed consent.
• The participant has a clinical diagnosis of GD3 and a documented deficiency of acid β-glucosidase activity confirming the diagnosis of Gaucher disease.
• The participant has received ERT (Cerezyme or other ERT; as deemed appropriate by local regulations) for at least 2 years prior to enrollment, on a stable dose for at least 6 months and is within the therapeutic goals defined in I04 and is deemed clinically stable for at least 1 year by the Investigator.
• The participant has reached Gaucher disease therapeutic goals defined as all of the following: • Hemoglobin level of ≥11.0 g/dL

• Platelet count ≥100 000/mm3
• Spleen volume \<10 MN
• Liver volume \<1.5 MN
• No bone crisis and free of symptomatic bone disease such as bone pain attributable to osteonecrosis and/or pathological fractures within 3 months prior to screening
• If the participant has a history of seizures, they are well controlled under appropriate medication not identified as a strong or moderate inducer or inhibitor of CYP3A.
• The participant has been identified to present with gaze palsy, predominantly horizontal, with slow or absent saccades.
• Participants ≥10 kg of weight.

Exclusion Criteria:

• The participant is blood-transfusion dependent.
• The participant has prior esophageal varices or liver infarction or current liver enzymes (alanine aminotransferase \[ALT\]/ aspartate aminotransferase \[AST\]) or total bilirubin \>2 times the upper limit of normal, unless the participant has a diagnosis of Gilbert syndrome.
• The participant has any clinically significant disease, other than Gaucher disease, including cardiovascular (congenital cardiac defect, coronary artery disease, valve disease or left sided heart failure; clinically significant arrhythmias or conduction defect), hepatic, gastrointestinal, pulmonary, neurologic, endocrine, metabolic (eg, hypokalemia, hypomagnesemia) or psychiatric disease, other medical conditions, or serious intercurrent illnesses that may preclude participation in the opinion of the Investigator.
• The participant has renal insufficiency, as defined by an estimated glomerular filtration rate \<30 mL/min/1.73m2 at the screening visit (calculated by bedside Schwartz formula).
• The participant has a history of cancer, except for basal cell carcinoma.
• The participant has progressive myoclonic epilepsy.
• The participant requires use of invasive ventilatory support.
• The participant requires use of noninvasive ventilator support while awake for longer than 12 hours daily.
• The participant is scheduled for in-patient hospitalization including elective surgery, during the study.
• The participant has had a major organ transplant (eg, bone marrow or liver).
• The participant has a positive result of any of the following tests: anti-hepatitis C virus (anti- HCV) antibodies, anti-human immunodeficiency virus 1 or 2 antibodies (anti-HIV1 or anti-HIV2 Ab).
• With respect to hepatitis B testing, participants are excluded if they have either of the following:
• Positive hepatitis B surface antigen (HBsAg).
• Positive hepatitis B core antibody (HBcAb) and positive hepatitis B virus deoxyribonucleic acid (HBV DNA) test.
• The participant has had a total splenectomy prior to enrollment, or the participant has had a partial splenectomy within 3 years prior to randomization.
• The participant received chaperone therapy within 6 months, substrate reduction therapy other than venglustat within 6 months or venglustat substrate reduction therapy prior to enrollment. Chaperone therapy and substrate reduction therapy other than venglustat will need be discontinued at least 6 months prior to enrollment.
• The participant receives strong or moderate inducers or inhibitors (including food products eg, grapefruit juice double strength) of CYP3A for long term treatment that cannot be replaced.
• The participant has had exposure to any investigational drug within the last 30 days or 5 half-lives from screening, whichever is longer.
• The participant is currently participating in another investigational interventional study.
• The participant used venglustat within 3 months or 5 half-lives, whichever is longer, before study enrollment.
• The participant, in the opinion of the Investigator, is unable to adhere to the requirements of the study or unable to undergo study assessments (eg, contraindication for MRI).
• Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.

The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment

Random assignment

Masking

No masking

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Secondary measures

Research locations (0)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

No locations are listed. Use the official study contact.

Study team and timeline

Lead sponsor

Sanofi

Study start

Dec 11, 2026 Estimated

Primary completion

Jan 14, 2030 Estimated

Study completion

Mar 3, 2031 Estimated

First posted

Nov 10, 2026 Actual

Last updated

Nov 10, 2026 Actual

Official study contacts